NEW YORK (GenomeWeb News) – Bristol-Myers Squibb has renewed its license for Ingenuity Systems’ pathway analysis software for use in genomics and proteomics research aimed at advancing its drug discovery programs, Ingenuity said today.
Under the agreement, Bristol-Myers Squibb gains enterprise-wide access to the Ingenuity Pathways Analysis software for modeling, visualization, and interpretation of genomics and proteomics data. BMS has been an Ingenuity customer since 2004.
The IPA software supports data from a variety of experimental platforms and at “all stages of the drug discovery and development process,” including biomarker discovery, target identification and validation, pharmacogenomics, metabolomics, and molecular toxicology, Ingenuity said.
Financial terms of the agreement were not released.